Kalypsys, Inc. Initiates Phase IIa Clinical Trial of Topical iNOS Inhibitor

December 18, 2007 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

SAN DIEGO--(BUSINESS WIRE)--Kalypsys Inc. today announced the initiation of a Phase IIa clinical trial of KD7040, an inducible nitric oxide synthase (iNOS) inhibitor formulated as a topical gel, for the treatment of postherpetic neuralgia (PHN).

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2